about
State-of-the-Art Review on Diabetes Care in ItalyItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Estroprogestinic pill normalizes IGF-I levels in acromegalic women.Primary hyperparathyroidism and Klinefelter's syndrome in a young man.A 2016 Italian Survey about Guidelines and Clinical Management of Thyroid Nodules.An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.A 2015 Italian Survey of Clinical Practice Patterns in the Management of Graves' Disease: Comparison with European and North American SurveysItalian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.A 2016 Italian Survey about the Clinical Use of Selenium in Thyroid Disease.AME Position Statement on clinical management of acromegaly.Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA.NEPHROLITHIASIS IN PRIMARY HYPERPARATHYROIDISM: A COMPARISON BETWEEN SILENT AND SYMPTOMATIC PATIENTS.Forearm DXA Increases the Rate of Patients With Asymptomatic Primary Hyperparathyroidism Meeting Surgical Criteria.Mild primary hyperparathyroidism as defined in the Italian Society of Endocrinology's Consensus Statement: prevalence and clinical features.Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism.VITAMIN D DEFICIENCY DOES NOT AFFECT THE LIKELIHOOD OF PRESURGICAL LOCALIZATION IN ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM.Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?Efficacy of pasireotide in controlling severe hypercortisolism until cardiac transplantation.Perioperative cortisol can predict hypothalamus-pituitary-adrenal status in clinically non-functioning pituitary adenomas.Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.Raloxifene lowers IGF-I levels in acromegalic women.Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study.Silent renal stones in primary hyperparathyroidism: prevalence and clinical features.Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms.Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status.Decreased adrenergic tone in acromegaly: evidence from direct recording of muscle sympathetic nerve activity.Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.Memory impairment in Cushing's disease.Doxorubicin for acromegaly: a case report.Effect of simultaneous administration of GHRH (1-40) and TRH on GH, PRL and TSH secretion in normal man.Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults.THE CLINICAL PRESENTATION OF PRIMARY HYPERPARATHYROIDISM: A SOUTHERN EUROPEAN PERSPECTIVE OVER THE LAST TWO DECADESEffective long-term temozolomide rechallenge in a macroprolactinomaHyponatremia after anticoagulant treatment: a rare cause of adrenal failure
P50
Q26750821-6400D183-2C23-4413-A9EF-A84CC4F1984DQ34157385-8684E846-5BC7-45DF-91F3-DA00FF1BF8F5Q34211296-57BEF068-6B9C-4C73-B69B-49C71DA2FE1AQ35335658-CA64E456-3F2F-4294-9F8C-9B3FC5C79057Q36394563-2C38D6C8-CD55-4A6B-821A-54DFE3E4FF0CQ36906752-B3663262-245E-40ED-A64F-11ACCDD74682Q37104821-1EB7198F-E63E-4AE1-9593-47E857EE866FQ37135281-B276D96F-6560-429F-86B5-EA5F4CA2BD53Q37292997-156838DC-6E7E-4D5E-BDD5-B98005AA9B3AQ37387874-2334C2BC-A37B-4AF3-9C8F-EA24D902EA3DQ37634881-4B6BD0A8-42BE-47EF-B432-FD13A7326AE5Q39104763-3B4321C7-403F-45D4-A047-FA2DAB1E6161Q39209705-8063E833-D598-4D08-95BC-7470A61BBD6FQ39857499-DEED68AA-26F1-403E-B80C-E5CDDD1A04C9Q40259621-BB14D87A-6670-48E7-AC83-9F6C96A8A05EQ40830638-35EA1BCD-FC1F-4CA6-91E1-3450890936CCQ41159859-3FD52611-EA27-413C-80B9-BF748153FE82Q42169667-25119701-9EC8-4924-B717-F1340B87D97EQ42290552-CEDD623F-D4D4-4FBF-A19F-7929AB9BC2FEQ42454820-C258832C-98CF-459C-ADF6-2F4265208D3BQ42465149-05F71B63-D554-4FC9-893A-1E64F91615FBQ42490219-AB2E6072-36BC-4699-BAED-EE32C18181F5Q42505176-0403D8AA-800F-4A55-BBF4-D29B9E23A71FQ42511922-25BE8881-C404-441E-86C5-B7C17977E3BCQ42515604-927C7F5E-01CB-4791-B79D-50A3B018FCCBQ42632056-28086C7D-089F-4C20-93D6-5F9101210163Q44375682-15152891-9F5B-4E51-B20A-46E0CD6AB3AFQ44492739-1206A99A-E860-4399-975A-2702D4200E07Q46170669-6F9EAEB3-9800-4703-B5D9-474485ACD535Q47316227-164192B5-F813-4B78-B849-F6EFF03EC565Q47630955-7A2C4B58-5027-451F-B86D-5E8FEFE57C87Q48264914-88EF589C-E624-4A81-849B-0D5ED9608E20Q48359910-87F002B1-5124-495D-B12C-708B26441B30Q48362270-11FFE8DE-80D3-4DC9-89F4-032D4D2EB9DDQ48715840-275673C8-BAED-4DE1-807D-BE861708E95AQ51631933-E449FE88-B4A6-49A7-8563-6752F4352644Q54965822-C785C01B-9B10-427F-88BE-B3E35FC5B982Q56979891-A20FB5A2-A9E9-4B83-968D-56A6A4205382Q57299913-9A170F32-FAD6-45D9-A1D4-EFAD04BCBDEAQ57299916-B3AFBEE1-9984-4834-B65C-B91A337B0284
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto Attanasio
@ast
Roberto Attanasio
@en
Roberto Attanasio
@es
Roberto Attanasio
@nl
type
label
Roberto Attanasio
@ast
Roberto Attanasio
@en
Roberto Attanasio
@es
Roberto Attanasio
@nl
prefLabel
Roberto Attanasio
@ast
Roberto Attanasio
@en
Roberto Attanasio
@es
Roberto Attanasio
@nl
P106
P21
P31
P496
0000-0002-1417-287X